AUTHOR INDEX

Volume 76 • 1998

Abe, M., Nakai, H., Tabata, R., Saito, K. and Egawa, M.
Behavioral pharmacology of MKC-242 297
Aikawa, N. and Karasawa, A.
Anti-diarrheal effects of KW-5617 199
Akaike, A., Maeda, T., Kaneko, S. and Tamura, Y.
Neuroprotection by MKC-231 219
Akaike, A., Maeda, T., Kume, T. and Kaneko, S.
Neuroprotection by bifemelane 313
Akamatsu, Y. *See* Kaise, T.
Akiguchi, I. *See* Nishio, T.
Akiho, H., Iwai, A., Katoh-Sudoh, M., Tsukamoto, S., Koshiya, K. and Yamaguchi, T.
Neuroprotective effect of YM-39558 441
Aragane, K., Kusunoki, J., Kitamine, T., Yamaura, T. and Ohnishi, H.
Inhibitory action of F-1394 on liver ACAT 309
Arimura, S. *See* Sasa, H.

Cheng, Y.-W. *See* Kang, J.-J.
Chiba, S. *See* Imamura, H.
—— *See* Lakhe, M.
Chikahisa, L. *See* Oyama, Y.
Cho, T.-S. *See* Jung, Y.-S.
Cobbe, S.M. *See* Takahashi, S.

Denvir, M.A. *See* Takahashi, S.
Doi, T. *See* Kido, H.

Egawa, M. *See* Abe, M.
Esaki, K. *See* Hiroi, J.

Fu, W.-M. *See* Kang, J.-J.
Fujimura, A. *See* Sugimoto, K.
Fujisaki, H., Oketani, K., Nagakawa, J., Takenaka, O. and Yamanishi, Y.
Effects of rabeprazole on lysosomal enzymes 279
Fujita, Y. *See* Fukao, K.
Fukao, K., Momiyama, T., Ishihara, K., Ujihara, H., Fujita, Y., Taniyama, K., Serikawa, T. and Sasa, M.
GABA system on epileptic seizures in SER 387
Fukushima, S. *See* Takahashi, K.
Furukawa, S. *See* Nishio, T.
Furukawa, Y. *See* Imamura, H.
—— *See* Lakhe, M.
Furuya, M. *See* Okamoto, T.
Fushimi, K. *See* Hashimoto, Y.

Hamada, K., Yamazaki, J. and Nagao, T.
Potassium and monophasic action potential 149
Harada, Y. *See* Nosaka, C.
Harder, L. *See* Takahashi, S.
Haruno, I. *See* Nosaka, C.
Hashimoto, Y., Kurosawa, Y., Minami, K., Fushimi, K. and Narita, H.
Effects of 606A on cardiac hypertrophy 185
Hayano, C. *See* Hirotsu, I.
Hino, O. *See* Okamoto, T.
Hirata, A. *See* Oyama, Y.
Hirata, M., Kanematsu, T., Takeuchi, H. and Yagisawa, H.
Pleckstrin homology 255

Hiroi, J., Sengoku, T., Morita, K., Kishi, S., Sato, S., Ogawa, T., Tsudzuki, M., Matsuda, H., Wada, A. and Esaki, K.
FK506 inhibits dermatitis in NC mice 175
Hirose, M. *See* Lakhe, M.
Hirotsu, I., Hayano, C. and Tani, T.
Pelvic nerve and overflow incontinence 109
Ho, I.K. *See* Zhu, H.
Horie, K. *See* Onaya, J.
Horita, T. *See* Miyamoto, K.
Hoshi, K. *See* Satoh, K.
Hoyano, Y. *See* Imamura, H.

Ichihara, K. *See* Satoh, K.
Imagawa, T., Shida, M., Matsuzawa, K., Kaya, S. and Taniguchi, K.
Expression of heterogenous α1-subunits 415
Imai, S. *See* Kitagawa, T.
Imamura, H., Furukawa, Y., Kasama, M., Hoyano, Y., Yonezawa, T. and Chiba, S.
I_{Kr} inhibitors and vagal control 31
Ishibashi, T. *See* Kitagawa, T.
Ishihara, K. *See* Fukao, K.
—— *See* Saitoh, T.
Ishikawa, H. *See* Nosaka, C.
Ishikawa, S. *See* Nosaka, C.
Isosaki, M. and Nakashima, Toshikatsu
Psychological stress 305
Ito, A. *See* Kido, H.
Iwai, A. *See* Akiho, H.
Iwao, H. *See* Uchida, J.
Izumi, M., Mitsui-Saito, M., Ozaki, H. and Karaki, H.
Cicletanine in vascular smooth muscle 57

Jung, Y.-S., Moon, C.-H., Cho, T.-S., Yoo, S.-E. and Shin, H.-S.
Cardioprotective effects of KR-30450 65

Kaise, T., Akamatsu, Y. and Ohmori, K.
Effect of oxatomide on allergic rhinitis 223
Kaneko, S. *See* Akaike, A.
Kanemaru, K. *See* Oyama, Y.
Kanematsu, T. *See* Hirata, M.
Kang, J.-J., Cheng, Y.-W. and Fu, W.-M.
Neuromuscular blockade by boldine 207
Karaki, H. *See* Izumi, M.
Karasawa, A. *See* Aikawa, N.
Kasama, M. *See* Imamura, H.
Kase, H. *See* Nosaka, C.
Kashima, K. *See* Nakashima, Toshiaki
Katoh-Sudoh, M. *See* Akiho, H.
Kawakami, M. *See* Takahashi, S.
Kawashima, M. *See* Ogawa, A.
Kaya, S. *See* Imagawa, T.
Kido, H., Murakami, N., Ito, A., Kimura, K., Kodera, N., Doi, T. and Naruse, T.
Anti-inflammatory effects of M-5011 75
Kim, S. *See* Uchida, J.
Kimura, K. *See* Kido, H.
Kimura, M. and Ogihara, M.
PDGF and hepatocyte proliferation 165
Kishi, S. *See* Hiroi, J.

Kishimoto, T. *See* Uchida, J.
Kitagawa, T., Ishibashi, T. and Imai, S.
Diverse relaxation of coronary arteries 101
Kitamine, T. *See* Aragane, K.
Ko, F.-N. *See* Liao, C.-H.
Kobayashi, J. *See* Ohizumi, Y.
Kobayashi, M. *See* Sasa, H.
Kodera, N. *See* Kido, H.
Kokubo, S. *See* Takahashi, K.
Komori, S., Unno, T., Nakayama, T. and Ohashi, H.
M2 and M3 receptors and ionic current 213
Koshiya, K. *See* Akiho, H.
Kudo, Y. *See* Nishio, T.
Kume, T. *See* Akaike, A.
Kuo, S.-C. *See* Liao, C.-H.
Kuraishi, Y. *See* Okano, K.
Kurosawa, Y. *See* Hashimoto, Y.
Kusunoki, J. *See* Aragane, K.
Kyogashima, M. *See* Onaya, J.

Lakhe, M., Furukawa, Y., Yonezawa, T., Hirose, M., Nagashima, Y., Miyashita, Y. and Chiba, S.
EMD 57033 and EMD 53998 on sinus rate 435
Liao, C.-H., Ko, F.-N., Kuo, S.-C. and Teng, C.-M.
Antiplatelet effect of PP1D-1 141

MacFarlane, N.G. *See* Takahashi, S.
Maeda, T. *See* Akaike, A.
Maeguchi, M. *See* Ogawa, A.
Maruoka, Y., Ohno, Y., Tanaka, H., Yasuda, H., Otani, K., Tamamura, C. and Nakamura, M.
NMDA glycine-site antagonist and reflex 265
Masukawa, T., Nakanishi, K. and Natsuki, R.
NO and convulsions 425
Matsuda, H. *See* Hiroi, J.
Matsumoto, N. *See* Nakashima, Toshiaki
Matsunaga, K. *See* Ohizumi, Y.
Matsuzawa, K. *See* Imagawa, T.
Miller, D.J. *See* Takahashi, S.
Minami, K. *See* Hashimoto, Y.
Mineshita, S. *See* Xu, Z.-H.
Mishima, H.K. *See* Saitoh, T.
Mitsui-Saito, M. *See* Izumi, M.
Miura, K. *See* Uchida, J.
Miyake, H. *See* Nanri, M.
Miyamoto, K., Suzuki, R., Horita, T., Yamamoto, S., Waki, Y. and Takagi, K.
ALP activation by calcitonin in LLC-PK_1 cells 193
Miyashita, Y. *See* Lakhe, M.
Miyauchi, S. *See* Onaya, J.
Mizuno, S. *See* Onaya, J.
Momiyama, T. *See* Fukao, K.
Moon, C.-H. *See* Jung, Y.-S.
Morita, K. *See* Hiroi, J.
Murakami, N. *See* Kido, H.
Muraki, T. *See* Ogawa, A.
Murayama, T. and Nomura, Y.
The actions of NO and *S*-nitrosocysteine 129

Nagai, T. *See* Yamamoto, Takashi
Nagakawa, J. *See* Fujisaki, H.
Nagano, T. *See* Oyama, Y.
Nagao, T. *See* Hamada, K.
Nagashima, Y. *See* Lakhe, M.
Nakahata, N. *See* Rho, M.-C.
Nakai, H. *See* Abe, M.
Nakanishi, K. *See* Masukawa, T.
Nakashima, Toshiaki, Matsumoto, N. and Kashima, K.
Animal crude drugs and liver injury 271
Nakashima, Toshikatsu *See* Isosaki, M.
Nakata, H. *See* Sasa, H.
Nakata, M. *See* Oyama, Y.
Nakatani, K. *See* Ohizumi, Y.
Nakatani, T. *See* Uchida, J.
Nakayama, T. *See* Komori, S.
Namima, M. *See* Sasa, H.
Nanri, M., Yamamoto, J., Miyake, H. and Watanabe, H.
GTS-21 and cerebral ischemia in gerbils 23
Narita, H. *See* Hashimoto, Y.
Narita, M. and Tseng, L.F.
ε-Opioid receptor and its unique function 233
Naruse, T. *See* Kido, H.
Natsuki, R. *See* Masukawa, T.
Nishio, T., Sunohara, N., Furukawa, S., Akiguchi, I. and Kudo, Y.
NGF and nicergoline 321
Noguchi, S. *See* Oyama, Y.
Nomura, Y. *See* Murayama, T.
Nosaka, C., Ishikawa, H., Haruno, I., Yoshitomi, T., Kase, H., Ishikawa, S. and Harada, Y.
ET receptors in the rabbit iris 289

Ogawa, A., Maeguchi, M., Uchida, Y., Yoshioka, T., Kawashima, M. and Muraki, T.
Fibroblast inhibition by retinoids 317
Ogawa, T. *See* Hiroi, J.
Ogihara, M. *See* Kimura, M.
Ohashi, H. *See* Komori, S.
Ohizumi, Y., Matsunaga, K., Nakatani, K. and Kobayashi, J.
A novel activator of actomyosin ATPase 113
Ohizumi, Y. *See* Rho, M.-C.
Ohmori, K. *See* Kaise, T.
Ohnishi, H. *See* Aragane, K.
Ohno, K., Okada, M., Tsutsumi, R., Sakamoto, S. and Yamaguchi, T.
Effect of YM90K on excitotoxicity 105
Okabe, E. *See* Takahashi, S.
Okada, M. *See* Ohno, K.
Okamoto, T., Furuya, M., Yamakawa, T., Yamamura, K. and Hino, O.
TNF-α and IFN-γ induction 97
Okamura, T. *See* Toda, N.
Okano, K., Kuraishi, Y. and Satoh, M.
Spinal SP and EAA in hyperalgesia 15
Okazaki, E. *See* Oyama, Y.
Oketani, K. *See* Fujisaki, H.
Onaya, J., Kyogashima, M., Sunose, A., Miyauchi, S., Mizuno, S. and Horie, K.
Effects of dermatan sulfate on DIC rats 397
Oyama, Y., Chikahisa, L., Kanemaru, K., Nakata, M., Noguchi, S., Nagano, T., Okazaki, E. and Hirata, A.
Cytotoxic action of FTY720 377
Ozaki, H. *See* Izumi, M.

Rho, M.-C., Nakahata, N. and Ohizumi, Y.
12-HETE on ZT-A-induced aggregation 117
Rockhold, R.W. *See* Zhu, H.

Saito, K. and Sakai, K.
K_{ATP} channel and depressor effect of neuropeptides 227
Saito, K. *See* Abe, M.
Saitoh, T., Mishima, H.K., Shoge, K., Ishihara, K. and Sasa, M.
Acidosis suppressed glutamate toxicity 87

Sakai, K. *See* Saito, K.
Sakamoto, S. *See* Ohno, K.
Sasa, H., Nakata, H., Umekage, T., Namima, M., Tomiyama, K., Arimura, S., Kobayashi, M. and Watanabe, Y.
Growth factor effect on Ras GAP 121
Sasa, M. *See* Fukao, K.
—— *See* Saitoh, T.
Sato, S. *See* Hiroi, J.
Satoh, K., Yamamoto, A., Hoshi, K. and Ichihara, K.
Azelnidpine on stunned myocardium 369
Satoh, M. *See* Okano, K.
Sengoku, T. *See* Hiroi, J.
Serikawa, T. *See* Fukao, K.
Shida, M. *See* Imagawa, T.
Shimakura, K. *See* Xu, Z.-H.
Shimura, T. *See* Yamamoto, Takashi
Shin, H.-S. *See* Jung, Y.-S.
Shirahata, A. *See* Takahashi, K.
Shoge, K. *See* Saitoh, T.
Sugimoto, K. and Fujimura, A.
Role of kinins in cardiac hypertrophy 431
Sunohara, N. *See* Nishio, T.
Sunose, A. *See* Onaya, J.
Suzuki, R. *See* Miyamoto, K.

Tabata, R. *See* Abe, M.
Takagi, K. *See* Miyamoto, K.
Takahashi, K., Shirahata, A., Fukushima, S., Kokubo, S., Teramura, K. and Usuda, S.
Effects of YM175 on hypercalcemic rats 155
Takahashi, S., Denvir, M.A., Harder, L., Miller, D.J., Cobbe, S.M., Kawakami, M., MacFarlane, N.G. and Okabe, E.
Doxorubicin on 'chemically-skinned' muscle 405
Takenaka, O. *See* Fujisaki, H.
Takeuchi, H. *See* Hirata, M.
Tamura, Y. *See* Akaike, A.
Tani, T. *See* Hirotsu, I.
Taniguchi, K. *See* Imagawa, T.
Taniyama, K. *See* Fukao, K.
Teng, C.-M. *See* Liao, C.-H.
Teramura, K. *See* Takahashi, K.
Toda, N. and Okamura, T.
Cerebral vasodilators 349
Tomiyama, K. *See* Sasa, H.
Tseng, L.F. *See* Narita, M.
Tsudzuki, M. *See* Hiroi, J.
Tsukamoto, S. *See* Akiho, H.
Tsutsumi, R. *See* Ohno, K.

Uchida, J., Miura, K., Yamanaka, S., Kim, S., Iwao, H., Nakatani, T. and Kishimoto, T.
FK506 nephrotoxicity and endothelin 39
Uchida, Y. *See* Ogawa, A.
Ujihara, H. *See* Fukao, K.
Umekage, T. *See* Sasa, H.
Unno, T. *See* Komori, S.
Usuda, S. *See* Takahashi, K.

Wada, A. *See* Hiroi, J.
Waki, Y. *See* Miyamoto, K.
Wang, L.-M. *See* Xu, Z.-H.
Watanabe, H. *See* Nanri, M.
Watanabe, Y. *See* Sasa, H.

Xu, Z.-H., Shimakura, K., Yamamoto, Takatsugu, Wang, L.-M. and Mineshita, S.
Angiotensin I-induced pulmonary edema 51

Yagisawa, H. *See* Hirata, M.
Yamaguchi, T. *See* Akiho, H.
Yamakawa, T. *See* Okamoto, T.
Yamamoto, A. *See* Satoh, K.
Yamamoto, J.
Hippocampal theta-wave and emotionality 125
Yamamoto, J. *See* Nanri, M.
Yamamoto, S. *See* Miyamoto, K.
Yamamoto, Takashi, Nagai, T., Shimura, T. and Yasoshima, Y.
Neuroactive substances and taste function 325
Yamamoto, Takatsugu *See* Xu, Z.-H.
Yamamura, K. *See* Okamoto, T.
Yamanaka, S. *See* Uchida, J.
Yamanishi, Y. *See* Fujisaki, H.
Yamaura, T. *See* Aragane, K.
Yamazaki, J. *See* Hamada, K.
Yasoshima, Y. *See* Yamamoto, Takashi
Yonezawa, T. *See* Imamura, H.
—— *See* Lakhe, M.
Yoo, S.-E. *See* Jung, Y.-S.
Yoshioka, T. *See* Ogawa, A.
Yoshitomi, T. *See* Nosaka, C.

Zhu, H., Rockhold, R.W. and Ho, I.K.
Glutamate in opioid physical dependence 1

SUBJECT INDEX

Volume 76 • 1998

606A (2-propyl-3-[2′(1*H*-tetrazole-5-yl)biphenyl-4-yl]methyl-5-acetyl-4,5,6,7-tetrahydro imidazo[4,5-*c*]pyridine-4-carboxylic acid disodium salt) 185
6-*O*-Acetyl-9-methyl-7-bromoeudistomin D 113
Acetylcholine channel 207
Acidosis 87
Actomyosin ATPase 113
Acyl-CoA:cholesterol acyltransferase 309
α_1-Adrenoceptor agonist 165
Aged rat brain 321
Aggressive behavior 297
Alkaline phosphatase 193
Allergic rhinitis 223
Amino acid transporter 129
γ-Aminobutyric acid 387
Aminooxy-acetic acid 387
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) 105
Angiotensin I 51
Angiotensin converting enzyme 51
Angiotensin-converting enzyme inhibitor 431
Angiotensin II-receptor antagonist 185
Animal crude drug 271
Antinociception 233
Anxiolytic 297
Aorta (rat) 57, 305
Atopic dermatitis 175
ATP-sensitive potassium channel 149
Atypical endothelin receptor 289
Azelnidipine 369

Bear gall powder 271
Bethanechol 109
Bifemelane 313
Biliary secretion 279
Bisphosphonate 155
Boldine 207
Bone resorbing factor 155
Bovine gallstone 271
BQ-123 (cyclo (-D-Trp-D-Asp-Pro-D-Val-Leu)) 289
8-Br-cGMP (8-bromoguanosine 3′:5′ cyclic monophosphate sadium salt) 101
Bradykinin 431
Brain neuron 377
Butorphanol 1

Ca^{2+}-activated K^+ current 213
Ca^{2+} sensitivity 57, 405
Ca^{2+} sensitizer 435
Calcitonin 193
Carbachol 213
Carbon tetrachloride 271
Cardiac hypertrophy 185
Cardioprotection 65
Carrageenin 15
Cerebral artery 349
Cerebral cortex 219, 313
Cerebral ischemia 441
Chloroquine 279
Cicletanine 57
Collagen 317
Complete Freund's adjuvant 15
Conditioned taste aversion 325
Convulsion 425
Coronary artery 101
Cyclic GMP 57
Cytotoxic action 377

Depressor response 227
Dermal fibroblast 317
Dermatan sulfate 397
Descending enkephalinergic pathway 233
Diarrhea 199
Dihydropyridine derivative 369
Disopyramide 31
Disseminated intravascular coagulation 397
Dofetilide (*N*-[4-(2-[2-[4-(methanesulphonamide)phenoxy]-*N*-methylethylamino]ethyl)phenyl]-methanesulphonamide) 31
Doxorubicin 405

E-4031 (*N*-[4-[[1-[2-(6-methyl-2-pyridinyl)ethyl]-4-piperidinyl] carbonyl]phenyl]methanesulfonamide dihydrochloride dihydrate) 31
EMD 57033 ((+)-5-(1-(3,4-dimethoxybenzoyl)-1,2,3,4-tetrahydro-6-quinolyl)-6-methyl-3,6-dihydro-2*H*-1,3,4-thiadiazino-2-one) 435
Emotional activity 125
β-Endorphin 233
Endothelin 39
Endotoxin 397
Enkephalinergic pathway 233
Enoxacin 425
Epileptic seizure 387
Excitatory amino acid 15
Excitotoxicity 105
Experimental allergic rhinitis 223
Extracellular potassium 149

F-1394 ((1*S*,2*S*)-2-[3-(2,2-dimethylpropyl)-3-nonylureido]cyclohexane-1-yl 3-[(4*R*)-*N*-(2,2,5,5-tetramethyl-1,3-dioxane-4-carbonyl)amino]propionate) 309
Fibroblast (dermal) 317
FK506 (tacrolimus hydrate) 39, 175
Flow cytometry 377

Gastrointestinal propulsion 199
Glial cell 129
Glutamate 1, 87, 219, 313
Glyceryl trinitrate 101
Glycine-binding site 265
Growth factor 121
GTPase-activating protein 121
GTS-21 (3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride) 23

H^+,K^+-ATPase inhibitor 279
Heat shock protein 70 305
HeLa cell 415
Hemorrhagic tendency 397
Hepatocyte DNA synthesis 165
Hepatocyte proliferation 165
Hippocampal theta-wave 125
Hippocampus 129
5-HT_{1A} receptor 297
12*S*-Hydroxyeicosatetraenoic acid 117
Hypercalcemia 155

Immunoblot analysis 121
Immunosuppressant 377
Inositol phosphate 255
Inositol 1,4,5-trisphosphate 141
Interferon 97
Interleukin 1β 155
Interleukin-4 175
Intracellular calcium concentration 141
Ionomycin 117
Iris sphincter and dilator (rabbit) 289
Ischemia 23, 149, 369

K^+ channel (ATP-sensitive) 149
K_{ATP} channel activation 227
K^+ channel activator 65
K^+ current (Ca^{2+}-activated) 213
Kidney 193
KR-30450 (SKP-450) ((−)-(2*R*)-2-([1,3]-dioxolan-2-yl)-2-methyl-4-(2-oxopyrrolidin-1-yl)-6-nitro-2*H*-1-benzopyran) 65
KR-30818 (SKP-818) ((−)-(2*R*)-2-hydroxymethyl-2-methyl-4-(2-oxopyrrolidin-1-yl)-6-nitro-2*H*-1-benzopyran) 65
KW-5617 (zaldaride maleate) (1,3-dihydro-1-[1-[(4-methyl-4*H*,6*H*-pyrrolo[1,2-*a*][4,1]-benzoxazepin-4-yl)methyl]-4-piperidinyl]-2*H*-benzimidazol-2-one maleate) 199

Left ventricular hypertrophy 431
Lemakalim 65
Liver 271
LLC-PK_1 cell 193
Locus coeruleus 1
Loperamide 199
Losartan 51
Lysosomal enzyme 279

M-5011 (*d*-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid) 75
Marble burying behavior 297
Mast cell 175

MKC-231 (2-(2-oxopyrrolidin-1-yl)-*N*-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetoamide) 219
MKC-242 (5-{3-[((2*S*)-1,4-benzodioxan-2-ylmethyl)amino]propoxy}-1,3-benzodioxole HCl) 297
Mongolian gerbil 23
Monophasic action potential duration 149
Morphine 1
Muscarinic receptor 213
Muscimol 387
Myocardial stunning 369
Myofilament 405

N-methyl-D-aspartate (NMDA) receptor 1, 265
Na^+,K^+-ATPase 415
Nephrotoxicity 39
Nerve growth factor 321
Neuromodulator 325
Neuromuscular blockade 207
Neuropeptide 227, 325
Neurotoxicity 87
Neurotransmitter 325
Nicergoline 321
Nicotinic agonist 23
Nitric oxide 349
Nitric oxide synthase 425
S-Nitrosocysteine 129
Nonselective cationic current 213
Non-steroidal anti-inflammatory drug 75

ε-Opioid receptor 233
Orotic acid 441
Ouabain binding 415
Overflow incontinence 109
Oxatomide 223

Palatability 325
Parasympathetic nervous system 31
Parathyroid hormone-related protein 155
Patch-clamp 87
Pelvic nerve (rat) 109
Peumus boldus Mol. 207
Phentolamine 51
Phorbol ester 165
Phosphodiesterase 4 193
Phosphoinositide 255
Phosphorylation 415
Physical dependence 1
Platelet (rabbit) 141
Platelet-derived growth factor 165
Pleckstrin homology domain 255
Potassium channel (ATP-sensitive) 149
Potassium channel activator 65
PP1D-1 (2-chloro-3-methoxycarbonyl-propionamido-1,4-naphthoquinone) 141
Psychological stress 305
Pulmonary edema 51

Rabeprazole 279
Radioligand-receptor binding 289
Rb^+ uptake 415
Refractory period 31
Renal function 185
Retinal cell culture 87

Sarafotoxin 289
Sarcoplasmic reticulum 405
D-Serine 265
Signal transduction 255
Sinus rate 435
SKP-450 *See* KR-30450
SKP-818 *See* KR-30818
SM-18400 ((*S*)-9-chloro-5-[*p*-aminomethyl-*o*-(carboxymethoxy)phenylcarbamoyl-methyl]-6,7-dihydro-1*H*,5*H*-pyrido[1,2,3-*de*]quinoxaline-2,3-dione hydrochloride trihydrate) 265
Smooth muscle (vascular) 57
Smooth muscle (intestinal) 213
Spinal cord 15
Spinal reflex (in vitro) 265
Spontaneously hypertensive rats 39
Spontaneously epileptic rat 387
Stress 305
Substance P 15
Superprecipitation 113

T cell 175
Tacrolimus hydrate (FK506) 39, 175
TAK-044 ([cyclo D-α-aspartyl-3-[(4-phenyl-piperazin-1-yl)carbonyl]-L-alanyl-L-α-aspartyl-D-2-(2-thienyl)glycyl-L-leucyl-D-tryptophyl]disodium salt) 39
Taste aversion (conditioned) 325
Taste cell 325
Taste transduction 325
Tazarotene 317
THA (9-amino-1,2,3,4-tetrahydroacridine hydrochloride hydrate) 23
Thapsigargin 141
Theta-wave (hippocampal) 125
Thrombin clotting time 397
Thymocyte 129, 377
Transgenic mouse 97
Triton WR-1339 309
Tumor necrosis factor 97

Ulcerogenic activity 75

Vascular endothelium 185
Vasodilator intervention 349
Vasodilator nerve 349
Vasodilator substance 349
Ventricular trabeculae (rabbit) 405

Withdrawal 1

YM-39558 ((2,6-dioxo-1,2,3,6-tetrahydro-pyrimidine-4-carboxylic acid ethyl ester) 441
YM90K (6-(1*H*-imidazol-1-yl)-7-nitro-2,3(1*H*,4*H*)-quinoxalinedione monohydrochloride) 105

Zaldaride 199
Zooxanthellatoxin-A 117